Clinical Trial Update: The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL) [Phase 3]

View source ↗

Summary

A Phase 3 trial of EPA+DHA (SC401B) for lowering triglycerides in severe hypertriglyceridemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• EPA+DHA (SC401B) (eicosapentaenoic acid and docosahexaenoic acid)

Snippet

Sponsor: Sancilio and Company, Inc. | Conditions: Severe Hypertriglyceridemia | Phase 3 | Status: WITHDRAWN